Key statistics
As of last trade Abeona Therapeutics Inc (PCJ:BER) traded at 5.75, -30.39% below its 52-week high of 8.26, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.50 |
---|---|
High | 5.75 |
Low | 5.50 |
Bid | 5.80 |
Offer | 6.05 |
Previous close | 5.55 |
Average volume | 104.44 |
---|---|
Shares outstanding | 43.31m |
Free float | 41.09m |
P/E (TTM) | -- |
Market cap | 250.79m USD |
EPS (TTM) | -2.29 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:58 GMT.
More ▼
Announcements
- Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
- Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics® Announces Participation in November Investor Conferences
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
- Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
- Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
- Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
- Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
More ▼